Fig. 2From: Multicenter retrospective study on the use of Curebest™ 95GC Breast for estrogen receptor-positive and node-negative early breast cancerEvaluation of 95GC results and relapse outcome. Relapse-free survival was evaluated in patients included in the 95GC-L group (in blue) and 95GC-H group (in red) for up to 120 months post-surgery. The log-rank test was used to evaluate statistical differencesBack to article page